PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma

Lale Kostakoglu; Stéphane Chauvie

doi:10.1016/j.cpet.2019.03.002

PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma

PET Clin. 2019 Jul;14(3):317-329. doi: 10.1016/j.cpet.2019.03.002.

Authors

Lale Kostakoglu¹, Stéphane Chauvie²

Affiliations

¹ Nuclear Medicine and Molecular Imaging, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1141, New York, NY 10029, USA. Electronic address: Lale.kostakoglu@mssm.edu.
² Department of Medical Physics, 'Santa Croce e Carle' Hospital, Cuneo, Italy.

PMID: 31084772
DOI: 10.1016/j.cpet.2019.03.002

Abstract

Lymphoma is a potentially curable disease; however, the clinical challenge lies in further improvement of outcomes. PET with fludeoxyglucose is an effective imaging tool. PET-derived quantitative metrics have raised significant interest to be used as a prognostic factor to complement clinical parameters for treatment decisions. The most optimized use of these quantitative PET metrics, however, will be possible with the standardization of imaging procedures. In this article, we review the technical and methodological considerations related to PET-derived quantitative metrics, and the relevant published data to emphasize the potential value of these metrics in patient prognosis and treatment response in lymphoma.

Keywords: FDG-PET; Lymphoma; Prognosis; Quantitative metrics; Response.

Publication types

Review

MeSH terms

Evaluation Studies as Topic
Fluorodeoxyglucose F18*
Humans
Lymphoma / diagnostic imaging*
Lymphoma / therapy*
Positron-Emission Tomography / methods*
Prognosis
Radiopharmaceuticals
Treatment Outcome

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18